Monitoring Report: Respiratory Viruses – February 2025 Data

Samuel Gratzl*, PhD

Brianna M Goodwin Cartwright*, MS

Karen Gilbert, PhD

Nina Masters, MPH, PhD

Patricia J Rodriguez, PhD, MPH

Duy Do, PhD

Nicholas L Stucky, MD, PhD

*Denotes co-first author
Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:
Dr Nicholas Stucky
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: nicholass@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through March 02, 2025) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2020 and March 02, 2025. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 723,293 hospitalizations of 665,139 unique patients who tested positive for a respiratory virus between October 01, 2020 and March 02, 2025.

Overall, respiratory virus-associated hospitalizations declined throughout February 2025. By the last week of the month, respiratory virus-associated hospitalizations accounted for 6.0% of all hospitalizations, down from 9.6% in late January (-38.0%). Influenza remained the leading cause of virus-associated hospitalizations (3.5%), despite a sharp decline. COVID-, RSV-, and parainfluenza-associated hospitalizations also decreased, while HMPV saw a slight increase. In children aged 0–4 years, respiratory virus-associated hospitalizations remained stable at 4.9%. RSV hospitalizations rose (+29.3%) to 1.9% of all hospitalizations, while influenza hospitalizations dropped (-47.2%). Test positivity for HMPV, parainfluenza, and rhinovirus increased, with rhinovirus reaching the highest positivity rate (29.9%). Although influenza test positivity decreased for children, the rate remained high at 18.7%. Among older adults (65+), hospitalizations associated with respiratory viruses declined (-37.4%) to 7.5%. Influenza remained the most common virus-associated hospitalization (4.5%), despite a large drop (-46.3%). COVID- and RSV-associated hospitalizations also declined, while HMPV hospitalizations increased slightly. Test positivity trends mirrored these changes, with notable increases in HMPV and

rhinovirus. These findings highlight influenza's continued impact, alongside rising HMPV and rhinovirus activity.

Discussion: These data highlight the overall decline in respiratory virus-associated hospitalizations; however, the persistent burden of influenza, particularly in older adults, remains a concern. The sharp drop in influenza hospitalizations is encouraging, yet its continued prevalence underscores the need for ongoing monitoring. In pediatric populations, the stability of RSV-associated hospitalizations and the rise in HMPV suggest shifting trends in viral circulation, reinforcing the importance of targeted public health measures. While declines in several respiratory viruses are decreasing, the overall elevated rate of associated hospitalizations warrants close surveillance and potential intervention.

Trends in surveillance

Overall population

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
January 27, 2025	9.6%	1.8%	6.7%	0.1%	0.1%	0.9%	0.6%
February 24, 2025	6.0%	1.3%	3.5%	0.2%	0.1%	0.7%	0.5%
Change (percentage)	-38.0%	-28.1%	-47.7%	+72.6%	-30.6%	-21.4%	-2.1%
Difference (percentage points)	-3.7%	-0.5%	-3.2%	+0.1%	-0.0%	-0.2%	-0.0%

Change in positivity rate of weekly respiratory virus tests between January 27, 2025 and February 24, 2025

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
January 27, 2025	13.5%	5.6%	24.5%	1.2%	0.8%	5.3%	8.1%
February 24, 2025	9.3%	5.2%	16.3%	2.5%	1.1%	4.3%	9.5%
Change (percentage)	-30.9%	-7.9%	-33.6%	+104.3%	+34.6%	-19.2%	+17.6%
Difference (percentage points)	-4.2%	-0.4%	-8.3%	+1.3%	+0.3%	-1.0%	+1.4%

In the week ending February 24, 2025, respiratory virus-associated hospitalizations accounted for 6.0% of all hospitalizations, marking a decline of 38.0% from late January, when the rate was 9.6%. Influenza-associated hospitalizations reached a peak this month have started to decline; however, influenza-associated hospitalizations remain the leading cause of respiratory virus-associated hospitalizations among those studied in this report, with a current rate of 3.5%. COVID-associated hospitalizations also declined (-28.1%), along with parainfluenza (-30.6%), RSV (-21.4%), and rhinovirus (-2.1%). HMPV-associated hospitalizations saw a slight increase throughout February (+0.1 percentage points, 72.6% increase); however, test positivity for HMPV more than doubled (104.3%). While rhinovirus decreased overall throughout the month, the last week of February saw a slight increase and test positivity saw a 17.6% increase throughout the month. Parainfluenza test positivity also increased (34.6%) while test positivity for all other respiratory viruses decreased. Influenza test positivity remained high 16.3%.

Infants and children (age 0-4)

Change in rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions between January 27, 2025 and February 24, 2025 for infants and children under five

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
January 27, 2025	5.0%	1.0%	1.4%	0.2%	0.1%	1.4%	1.8%
February 24, 2025	4.9%	1.1%	0.7%	0.4%	0.2%	1.9%	2.0%
Change (percentage)	-2.5%	+8.6%	-47.2%	+111.2%	+76.0%	+29.3%	+9.1%
Difference (percentage points)	-0.1%	+0.1%	-0.6%	+0.2%	+0.1%	+0.4%	+0.2%

Change in weekly test positivity rate between January 27, 2025 and February 24, 2025 for infants and children under five

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
January 27, 2025	17.3%	5.5%	27.5%	2.8%	2.2%	16.6%	25.6%
February 24, 2025	13.0%	5.6%	18.7%	5.7%	4.7%	12.6%	29.9%
Change (percentage)	-24.7%	+1.7%	-32.0%	+105.0%	+109.7%	-24.2%	+16.6%
Difference (percentage points)	-4.3%	+0.1%	-8.8%	+2.9%	+2.4%	-4.0%	+4.3%

In the population aged 0–4 years, respiratory virus-associated hospitalizations remained relatively stable between the weeks of January 27 and February 24, 2025, and are now at a rate of 4.9% of all hospitalizations in this age group. RSV-associated hospitalizations, which previously saw a high point before decreasing, saw a notable increase (+29.3%), now accounting for 1.9% of all hospitalizations. However, test positivity for RSV declined over the month (-24.2%). HMPV hospitalizations more than

doubled (+111.2%), though they still represent a small fraction of the total hospitalizations (0.4% of all hospitalizations). Parainfluenza- and rhinovirus-associated hospitalizations also rose slightly. In contrast, influenza-associated hospitalizations dropped sharply (-47.2%), accounting for just 0.7% of hospitalizations in this group during the last week of February. COVID-associated hospitalizations remained relatively stable, with a slight increase of 8.6%. HMPV and parainfluenza test positivity saw the largest increases (+105.0% and +109.7%, respectively), while rhinovirus positivity also rose (+16.6%), reaching 29.9%—the highest test positivity among all viruses studied. Meanwhile, influenza test positivity saw a sharp decline (-32.0%). COVID test positivity remained stable, with a slight increase of 1.7%.

Older adults (age 65 and over)

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
January 27, 2025	11.9%	2.5%	8.4%	0.1%	0.1%	1.1%	0.4%
February 24, 2025	7.5%	1.8%	4.5%	0.2%	0.1%	0.9%	0.4%
Change (percentage)	-37.4%	-29.9%	-46.3%	+71.4%	-11.8%	-20.3%	-2.7%
Difference (percentage points)	-4.5%	-0.8%	-3.9%	+0.1%	-0.0%	-0.2%	-0.0%

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
January 27, 2025	9.6%	6.9%	18.2%	1.0%	0.5%	3.6%	3.2%

Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
February 24, 2025	6.8%	6.1%	11.9%	1.8%	0.5%	3.0%	4.2%
Change (percentage)	-28.7%	-12.6%	-34.7%	+81.5%	+10.8%	-16.5%	+29.1%
Difference (percentage points)	-2.8%	-0.9%	-6.3%	+0.8%	+0.1%	-0.6%	+0.9%

Among older adults (age 65 and over), respiratory virus-associated hospitalizations declined by 37.4% between the weeks of January 27 and February 24, 2025, now accounting for 7.5% of all hospitalizations in this age group. While most virus-associated hospitalizations decreased, HMPV hospitalizations rose (+71.4%), though they still represent a small fraction of overall hospitalizations (0.2% of all hospitalizations in this age group). Influenza-associated hospitalizations saw the largest decline (-46.3%), however it remains the virus associated with the most hospitalizations at 4.5% of all hospitalizations in this age group. COVID- (-29.9%) and RSV-associated (-20.3%) hospitalizations also decreased over the month of February; however, both still make up 1.8% and 0.9% of all hospitalizations in this age group, respectively. Parainfluenza and rhinovirus hospitalizations remained relatively stable, with only minor changes (-11.8% and -2.7%, respectively). HMPV test positivity experienced the most substantial increase (+81.5%), followed by a moderate rise in rhinovirus (+29.1%) and a slight uptick in parainfluenza (+10.8%). Meanwhile, influenza test positivity dropped considerably (-34.7%), alongside RSV (-16.5%) and COVID (-12.6%). Despite the decline, influenza test positivity rates remained the highest at a rate of 11.9%. Rhinovirus positivity also rose to 4.2%, making it another virus to watch in this age group.

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death especially in vulnerable populations, such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza,

older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2020 and March 02, 2025 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on March 19, 2025 and included de-identified patient care data primarily located across ten

states: New York, Florida, Virginia, California, Illinois, Ohio, Washington, North Carolina, Wisconsin, and Louisiana.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Test positivity rate analysis

Lab results with known results were summarized over time by virus. The positivity rate was calculated monthly as the number of positive lab results divided by the total number of lab results with known results in that month.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 723,293 hospitalizations of 665,139 unique patients (Table 1).

Table 1: Patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	176,353 (100.00%)	183,016 (100.00%)	127,630 (100.00%)	118,368 (100.00%)	59,772 (100.00%)	665,139 (100.00%)
Age Group						
< 6 months	1,291 (0.73%)	2,480 (1.36%)	3,107 (2.43%)	2,432 (2.05%)	908 (1.52%)	10,218 (1.54%)
6 - <12 months	503 (0.29%)	1,111 (0.61%)	1,479 (1.16%)	1,244 (1.05%)	583 (0.98%)	4,920 (0.74%)
1 - <2 years	900 (0.51%)	1,691 (0.92%)	2,039 (1.60%)	1,702 (1.44%)	915 (1.53%)	7,247 (1.09%)
2 - 4 years	1,048 (0.59%)	2,484 (1.36%)	3,164 (2.48%)	2,214 (1.87%)	1,206 (2.02%)	10,116 (1.52%)
5 - 17 years	1,862 (1.06%)	3,190 (1.74%)	3,594 (2.82%)	3,102 (2.62%)	1,605 (2.69%)	13,353 (2.01%)
18 - 49 years	40,204 (22.80%)	38,809 (21.21%)	17,862 (14.00%)	15,783 (13.33%)	8,341 (13.95%)	120,999 (18.19%)
50 - 64 years	44,491 (25.23%)	37,602 (20.55%)	20,287 (15.90%)	19,391 (16.38%)	10,717 (17.93%)	132,488 (19.92%)
65 - 74 years	36,742 (20.83%)	36,776 (20.09%)	25,153 (19.71%)	24,040 (20.31%)	12,568 (21.03%)	135,279 (20.34%)
75 - 84 years	31,349 (17.78%)	35,806 (19.56%)	29,566 (23.17%)	28,597 (24.16%)	13,855 (23.18%)	139,173 (20.92%)
85+ years	17,963 (10.19%)	23,067 (12.60%)	21,379 (16.75%)	19,863 (16.78%)	9,074 (15.18%)	91,346 (13.73%)
Sex						
Female	85,876 (48.70%)	93,941 (51.33%)	66,794 (52.33%)	61,634 (52.07%)	31,552 (52.79%)	339,797 (51.09%)
Male	88,720 (50.31%)	87,287 (47.69%)	59,706 (46.78%)	55,384 (46.79%)	27,592 (46.16%)	318,689 (47.91%)
Other	2 (0.00%)	2 (0.00%)	4 (0.00%)	1 (0.00%)	0	9 (0.00%)
Unknown	1,755 (1.00%)	1,786 (0.98%)	1,126 (0.88%)	1,349 (1.14%)	628 (1.05%)	6,644 (1.00%)
Race						
White	110,398 (62.60%)	121,811 (66.56%)	84,970 (66.58%)	74,339 (62.80%)	37,921 (63.44%)	429,439 (64.56%)
Black or African American	20,444 (11.59%)	20,783 (11.36%)	13,842 (10.85%)	13,534 (11.43%)	7,741 (12.95%)	76,344 (11.48%)
Asian	4,344 (2.46%)	4,339 (2.37%)	4,134 (3.24%)	3,287 (2.78%)	1,475 (2.47%)	17,579 (2.64%)
Native Hawaiian or Other Pacific Islander	894 (0.51%)	932 (0.51%)	650 (0.51%)	633 (0.53%)	324 (0.54%)	3,433 (0.52%)
American Indian or Alaska Native	1,014 (0.57%)	1,119 (0.61%)	806 (0.63%)	656 (0.55%)	346 (0.58%)	3,941 (0.59%)
Other Race	12,199 (6.92%)	10,233 (5.59%)	8,335 (6.53%)	7,215 (6.10%)	3,553 (5.94%)	41,535 (6.24%)
Unknown	27,060 (15.34%)	23,799 (13.00%)	14,893 (11.67%)	18,704 (15.80%)	8,412 (14.07%)	92,868 (13.96%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Ethnicity						
Hispanic or Latino	20,272 (11.50%)	16,878 (9.22%)	13,174 (10.32%)	12,889 (10.89%)	6,798 (11.37%)	70,011 (10.53%)
Not Hispanic or Latino	130,030 (73.73%)	143,616 (78.47%)	100,036 (78.38%)	94,103 (79.50%)	49,029 (82.03%)	516,814 (77.70%)
Unknown	26,051 (14.77%)	22,522 (12.31%)	14,420 (11.30%)	11,376 (9.61%)	3,945 (6.60%)	78,314 (11.77%)
Virus						
COVID	165,226 (93.69%)	159,079 (86.92%)	77,519 (60.74%)	64,391 (54.40%)	16,120 (26.97%)	482,335 (72.52%)
HMPV	88 (0.05%)	2,313 (1.26%)	4,042 (3.17%)	3,405 (2.88%)	930 (1.56%)	10,778 (1.62%)
RSV	2,038 (1.16%)	4,451 (2.43%)	8,082 (6.33%)	10,194 (8.61%)	7,087 (11.86%)	31,852 (4.79%)
influenza	404 (0.23%)	4,919 (2.69%)	17,739 (13.90%)	21,518 (18.18%)	27,236 (45.57%)	71,816 (10.80%)
parainfluenza	1,495 (0.85%)	2,422 (1.32%)	4,399 (3.45%)	3,830 (3.24%)	1,149 (1.92%)	13,295 (2.00%)
rhinovirus	7,102 (4.03%)	9,832 (5.37%)	15,849 (12.42%)	15,030 (12.70%)	7,250 (12.13%)	55,063 (8.28%)
Comorbidity						
Asthma	14,968 (8.49%)	18,404 (10.06%)	15,708 (12.31%)	16,227 (13.71%)	9,164 (15.33%)	74,471 (11.20%)
Chronic Lung Disease	11,393 (6.46%)	12,419 (6.79%)	9,895 (7.75%)	10,052 (8.49%)	5,870 (9.82%)	49,629 (7.46%)
Chronic Obstructive Pulmonary Disease	19,937 (11.31%)	27,333 (14.93%)	22,873 (17.92%)	23,654 (19.98%)	13,123 (21.96%)	106,920 (16.07%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020

Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020

Test positivity rate over time

We included 53,229,423 lab results with known results of which 5,046,475 were positive. The test positivity rate is shown in Figure 3.

Figure 3: Weekly test positivity rate since October 2020

COVID-19

Our COVID study population consists of 500,047 hospitalizations of 482,335 unique patients (Table 2).

Table 2: COVID patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	165,226 (100.00%)	159,079 (100.00%)	77,519 (100.00%)	64,391 (100.00%)	16,120 (100.00%)	482,335 (100.00%)
Age Group						
< 6 months	325 (0.20%)	778 (0.49%)	423 (0.55%)	373 (0.58%)	176 (1.09%)	2,075 (0.43%)
6 - <12 months	55 (0.03%)	267 (0.17%)	207 (0.27%)	223 (0.35%)	105 (0.65%)	857 (0.18%)
1 - <2 years	105 (0.06%)	276 (0.17%)	188 (0.24%)	260 (0.40%)	213 (1.32%)	1,042 (0.22%)
2 - 4 years	131 (0.08%)	416 (0.26%)	258 (0.33%)	304 (0.47%)	310 (1.92%)	1,419 (0.29%)
5 - 17 years	949 (0.57%)	1,452 (0.91%)	603 (0.78%)	623 (0.97%)	466 (2.89%)	4,093 (0.85%)
18 - 49 years	38,207 (23.12%)	35,285 (22.18%)	10,203 (13.16%)	6,959 (10.81%)	1,531 (9.50%)	92,185 (19.11%)
50 - 64 years	42,732 (25.86%)	34,031 (21.39%)	11,866 (15.31%)	9,335 (14.50%)	2,124 (13.18%)	100,088 (20.75%)
65 - 74 years	35,298 (21.36%)	33,129 (20.83%)	16,429 (21.19%)	13,844 (21.50%)	3,276 (20.32%)	101,976 (21.14%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
75 - 84 years	30,156 (18.25%)	32,507 (20.43%)	21,185 (27.33%)	18,726 (29.08%)	4,578 (28.40%)	107,152 (22.22%)
85+ years	17,268 (10.45%)	20,938 (13.16%)	16,157 (20.84%)	13,744 (21.34%)	3,341 (20.73%)	71,448 (14.81%)
Sex						
Female	80,176 (48.53%)	81,485 (51.22%)	40,014 (51.62%)	32,628 (50.67%)	8,138 (50.48%)	242,441 (50.26%)
Male	83,385 (50.47%)	76,002 (47.78%)	36,792 (47.46%)	30,955 (48.07%)	7,790 (48.33%)	234,924 (48.71%)
Other	2 (0.00%)	2 (0.00%)	2 (0.00%)	1 (0.00%)	0	7 (0.00%)
Unknown	1,663 (1.01%)	1,590 (1.00%)	711 (0.92%)	807 (1.25%)	192 (1.19%)	4,963 (1.03%)
Race						
White	103,826 (62.84%)	106,785 (67.13%)	53,460 (68.96%)	42,085 (65.36%)	10,567 (65.55%)	316,723 (65.66%)
Black or African American	18,695 (11.31%)	17,639 (11.09%)	7,520 (9.70%)	6,504 (10.10%)	1,808 (11.22%)	52,166 (10.82%)
Asian	3,982 (2.41%)	3,461 (2.18%)	2,267 (2.92%)	1,829 (2.84%)	481 (2.98%)	12,020 (2.49%)
Native Hawaiian or Other Pacific Islander	824 (0.50%)	723 (0.45%)	295 (0.38%)	275 (0.43%)	47 (0.29%)	2,164 (0.45%)
American Indian or Alaska Native	940 (0.57%)	941 (0.59%)	406 (0.52%)	336 (0.52%)	89 (0.55%)	2,712 (0.56%)
Other Race	11,019 (6.67%)	8,157 (5.13%)	4,069 (5.25%)	3,050 (4.74%)	867 (5.38%)	27,162 (5.63%)
Unknown	25,940 (15.70%)	21,373 (13.44%)	9,502 (12.26%)	10,312 (16.01%)	2,261 (14.03%)	69,388 (14.39%)
Ethnicity						
Hispanic or Latino	18,896 (11.44%)	13,844 (8.70%)	6,307 (8.14%)	5,527 (8.58%)	1,333 (8.27%)	45,907 (9.52%)
Not Hispanic or Latino	121,498 (73.53%)	125,043 (78.60%)	61,554 (79.41%)	52,116 (80.94%)	13,551 (84.06%)	373,762 (77.49%)
Unknown	24,832 (15.03%)	20,192 (12.69%)	9,658 (12.46%)	6,748 (10.48%)	1,236 (7.67%)	62,666 (12.99%)
Comorbidity						
Asthma	13,115 (7.94%)	14,611 (9.18%)	7,821 (10.09%)	7,490 (11.63%)	2,045 (12.69%)	45,082 (9.35%)
Chronic Lung Disease	10,412 (6.30%)	10,356 (6.51%)	5,589 (7.21%)	5,253 (8.16%)	1,397 (8.67%)	33,007 (6.84%)
Chronic Obstructive Pulmonary Disease	18,051 (10.93%)	23,049 (14.49%)	13,428 (17.32%)	12,795 (19.87%)	3,346 (20.76%)	70,669 (14.65%)

Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 4. Figure 5 shows seasonal trends.

Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2020

Figure 5: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 28,708,573 COVID lab results with known results of which 3,322,915 were positive. The COVID test positivity rate is shown in Figure 6. Figure 7 shows yearly trends.

Figure 6: Weekly COVID test positivity rate since October 2020

Figure 7: Weekly COVID test positivity rate by season

Influenza

Our influenza study population consists of 82,824 hospitalizations of 71,816 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	404 (100.00%)	4,919 (100.00%)	17,739 (100.00%)	21,518 (100.00%)	27,236 (100.00%)	71,816 (100.00%)
Age Group						
< 6 months	3 (0.74%)	28 (0.57%)	81 (0.46%)	87 (0.40%)	53 (0.19%)	252 (0.35%)
6 - <12 months	1 (0.25%)	18 (0.37%)	69 (0.39%)	52 (0.24%)	41 (0.15%)	181 (0.25%)
1 - <2 years	0	29 (0.59%)	121 (0.68%)	86 (0.40%)	86 (0.32%)	322 (0.45%)
2 - 4 years	4 (0.99%)	60 (1.22%)	264 (1.49%)	207 (0.96%)	140 (0.51%)	675 (0.94%)
5 - 17 years	6 (1.49%)	181 (3.68%)	600 (3.38%)	566 (2.63%)	422 (1.55%)	1,775 (2.47%)
18 - 49 years	112 (27.72%)	1,116 (22.69%)	3,524 (19.87%)	4,389 (20.40%)	4,292 (15.76%)	13,433 (18.70%)
50 - 64 years	103 (25.50%)	914 (18.58%)	3,698 (20.85%)	4,862 (22.60%)	5,807 (21.32%)	15,384 (21.42%)
65 - 74 years	71 (17.57%)	986 (20.04%)	3,805 (21.45%)	4,657 (21.64%)	6,350 (23.31%)	15,869 (22.10%)
75 - 84 years	74 (18.32%)	964 (19.60%)	3,548 (20.00%)	4,306 (20.01%)	6,270 (23.02%)	15,162 (21.11%)
85+ years	30 (7.43%)	623 (12.67%)	2,029 (11.44%)	2,306 (10.72%)	3,775 (13.86%)	8,763 (12.20%)
Sex						
Female	245 (60.64%)	2,774 (56.39%)	9,901 (55.81%)	11,734 (54.53%)	14,786 (54.29%)	39,440 (54.92%)
Male	154 (38.12%)	2,098 (42.65%)	7,698 (43.40%)	9,576 (44.50%)	12,177 (44.71%)	31,703 (44.14%)
Other	0	0	2 (0.01%)	0	0	2 (0.00%)
Unknown	5 (1.24%)	47 (0.96%)	138 (0.78%)	208 (0.97%)	273 (1.00%)	671 (0.93%)
Race						
White	254 (62.87%)	3,280 (66.68%)	11,634 (65.58%)	12,911 (60.00%)	17,300 (63.52%)	45,379 (63.19%)
Black or African American	72 (17.82%)	672 (13.66%)	2,367 (13.34%)	3,033 (14.10%)	3,691 (13.55%)	9,835 (13.69%)
Asian	6 (1.49%)	101 (2.05%)	451 (2.54%)	525 (2.44%)	615 (2.26%)	1,698 (2.36%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Native Hawaiian or Other Pacific Islander	2 (0.50%)	41 (0.83%)	113 (0.64%)	149 (0.69%)	134 (0.49%)	439 (0.61%)
American Indian or Alaska Native	2 (0.50%)	46 (0.94%)	150 (0.85%)	132 (0.61%)	160 (0.59%)	490 (0.68%)
Other Race	13 (3.22%)	253 (5.14%)	1,105 (6.23%)	1,308 (6.08%)	1,450 (5.32%)	4,129 (5.75%)
Unknown	55 (13.61%)	526 (10.69%)	1,919 (10.82%)	3,460 (16.08%)	3,886 (14.27%)	9,846 (13.71%)
Ethnicity						
Hispanic or Latino	33 (8.17%)	499 (10.14%)	2,059 (11.61%)	2,532 (11.77%)	3,037 (11.15%)	8,160 (11.36%)
Not Hispanic or Latino	307 (75.99%)	3,925 (79.79%)	14,052 (79.22%)	17,206 (79.96%)	22,524 (82.70%)	58,014 (80.78%)
Unknown	64 (15.84%)	495 (10.06%)	1,628 (9.18%)	1,780 (8.27%)	1,675 (6.15%)	5,642 (7.86%)
Comorbidity						
Asthma	38 (9.41%)	764 (15.53%)	2,767 (15.60%)	3,426 (15.92%)	4,283 (15.73%)	11,278 (15.70%)
Chronic Lung Disease	29 (7.18%)	455 (9.25%)	1,613 (9.09%)	2,002 (9.30%)	2,859 (10.50%)	6,958 (9.69%)
Chronic Obstructive Pulmonary Disease	67 (16.58%)	1,067 (21.69%)	3,845 (21.68%)	4,644 (21.58%)	6,269 (23.02%)	15,892 (22.13%)

Hospitalization rate over time

The rate of influenza-associated hospitalization is shown in Figure 8. Figure 9 shows seasonal trends.

Figure 8: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2020

Figure 9: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 13,479,554 influenza lab results with known results of which 1,082,335 were positive. The influenza test positivity rate is shown in Figure 10. Figure 11 shows yearly trends.

Figure 10: Weekly influenza test positivity rate since October 2020

Figure 11: Weekly influenza test positivity rate by season

Human metapneumovirus (HMPV)

Our HMPV study population consists of 15,079 hospitalizations of 10,778 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	88 (100.00%)	2,313 (100.00%)	4,042 (100.00%)	3,405 (100.00%)	930 (100.00%)	10,778 (100.00%)
Age Group						
< 6 months	2 (2.27%)	57 (2.46%)	139 (3.44%)	69 (2.03%)	12 (1.29%)	279 (2.59%)
6 - <12 months	1 (1.14%)	67 (2.90%)	102 (2.52%)	80 (2.35%)	18 (1.94%)	268 (2.49%)
1 - <2 years	8 (9.09%)	124 (5.36%)	144 (3.56%)	79 (2.32%)	18 (1.94%)	373 (3.46%)
2 - 4 years	12 (13.64%)	182 (7.87%)	245 (6.06%)	130 (3.82%)	27 (2.90%)	596 (5.53%)
5 - 17 years	2 (2.27%)	97 (4.19%)	141 (3.49%)	92 (2.70%)	25 (2.69%)	357 (3.31%)
18 - 49 years	12 (13.64%)	274 (11.85%)	430 (10.64%)	421 (12.36%)	108 (11.61%)	1,245 (11.55%)
50 - 64 years	21 (23.86%)	427 (18.46%)	678 (16.77%)	611 (17.94%)	155 (16.67%)	1,892 (17.55%)
65 - 74 years	8 (9.09%)	423 (18.29%)	786 (19.45%)	696 (20.44%)	168 (18.06%)	2,081 (19.31%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
75 - 84 years	14 (15.91%)	420 (18.16%)	842 (20.83%)	749 (22.00%)	246 (26.45%)	2,271 (21.07%)
85+ years	8 (9.09%)	242 (10.46%)	535 (13.24%)	478 (14.04%)	153 (16.45%)	1,416 (13.14%)
Sex						
Female	42 (47.73%)	1,336 (57.76%)	2,350 (58.14%)	2,080 (61.09%)	539 (57.96%)	6,347 (58.89%)
Male	44 (50.00%)	959 (41.46%)	1,668 (41.27%)	1,303 (38.27%)	377 (40.54%)	4,351 (40.37%)
Unknown	2 (2.27%)	18 (0.78%)	24 (0.59%)	22 (0.65%)	14 (1.51%)	80 (0.74%)
Race						
White	57 (64.77%)	1,667 (72.07%)	2,868 (70.95%)	2,135 (62.70%)	636 (68.39%)	7,363 (68.32%)
Black or African American	8 (9.09%)	241 (10.42%)	354 (8.76%)	360 (10.57%)	82 (8.82%)	1,045 (9.70%)
Asian	1 (1.14%)	45 (1.95%)	114 (2.82%)	71 (2.09%)	18 (1.94%)	249 (2.31%)
Native Hawaiian or Other Pacific Islander	0	17 (0.73%)	13 (0.32%)	8 (0.23%)	2 (0.22%)	40 (0.37%)
American Indian or Alaska Native	0	12 (0.52%)	34 (0.84%)	17 (0.50%)	4 (0.43%)	67 (0.62%)
Other Race	10 (11.36%)	108 (4.67%)	285 (7.05%)	260 (7.64%)	64 (6.88%)	727 (6.75%)
Unknown	12 (13.64%)	223 (9.64%)	374 (9.25%)	554 (16.27%)	124 (13.33%)	1,287 (11.94%)
Ethnicity						
Hispanic or Latino	19 (21.59%)	230 (9.94%)	561 (13.88%)	498 (14.63%)	139 (14.95%)	1,447 (13.43%)
Not Hispanic or Latino	55 (62.50%)	1,859 (80.37%)	3,167 (78.35%)	2,648 (77.77%)	725 (77.96%)	8,454 (78.44%)
Unknown	14 (15.91%)	224 (9.68%)	314 (7.77%)	259 (7.61%)	66 (7.10%)	877 (8.14%)
Comorbidity						
Asthma	11 (12.50%)	367 (15.87%)	646 (15.98%)	556 (16.33%)	164 (17.63%)	1,744 (16.18%)
Chronic Lung Disease	10 (11.36%)	281 (12.15%)	435 (10.76%)	339 (9.96%)	108 (11.61%)	1,173 (10.88%)
Chronic Obstructive Pulmonary Disease	17 (19.32%)	511 (22.09%)	832 (20.58%)	687 (20.18%)	220 (23.66%)	2,267 (21.03%)

Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 12. Figure 13 shows seasonal trends.

Figure 12: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2020

Figure 13: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 1,667,327 HMPV lab results with known results of which 40,824 were positive. The HMPV test positivity rate is shown in Figure 14. Figure 15 shows yearly trends.

Figure 14: Weekly HMPV test positivity rate since October 2020

Figure 15: Weekly HMPV test positivity rate by season

Parainfluenza virus

Our parainfluenza study population consists of 16,244 hospitalizations of 13,295 unique patients (Table 5).

Table 5: Parainfluenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	1,495 (100.00%)	2,422 (100.00%)	4,399 (100.00%)	3,830 (100.00%)	1,149 (100.00%)	13,295 (100.00%)
Age Group						
< 6 months	79 (5.28%)	124 (5.12%)	210 (4.77%)	123 (3.21%)	25 (2.18%)	561 (4.22%)
6 - <12 months	62 (4.15%)	89 (3.67%)	147 (3.34%)	79 (2.06%)	13 (1.13%)	390 (2.93%)
1 - <2 years	99 (6.62%)	117 (4.83%)	172 (3.91%)	129 (3.37%)	32 (2.79%)	549 (4.13%)
2 - 4 years	117 (7.83%)	200 (8.26%)	260 (5.91%)	152 (3.97%)	41 (3.57%)	770 (5.79%)
5 - 17 years	88 (5.89%)	128 (5.28%)	214 (4.86%)	123 (3.21%)	44 (3.83%)	597 (4.49%)
18 - 49 years	201 (13.44%)	300 (12.39%)	501 (11.39%)	420 (10.97%)	172 (14.97%)	1,594 (11.99%)
50 - 64 years	272 (18.19%)	418 (17.26%)	747 (16.98%)	705 (18.41%)	199 (17.32%)	2,341 (17.61%)
65 - 74 years	242 (16.19%)	427 (17.63%)	764 (17.37%)	763 (19.92%)	260 (22.63%)	2,456 (18.47%)
75 - 84 years	216 (14.45%)	357 (14.74%)	820 (18.64%)	831 (21.70%)	223 (19.41%)	2,447 (18.41%)
85+ years	119 (7.96%)	262 (10.82%)	564 (12.82%)	505 (13.19%)	140 (12.18%)	1,590 (11.96%)
Sex						
Female	776 (51.91%)	1,338 (55.24%)	2,370 (53.88%)	2,075 (54.18%)	627 (54.57%)	7,186 (54.05%)
Male	706 (47.22%)	1,067 (44.05%)	1,989 (45.21%)	1,710 (44.65%)	511 (44.47%)	5,983 (45.00%)
Unknown	13 (0.87%)	17 (0.70%)	40 (0.91%)	45 (1.17%)	11 (0.96%)	126 (0.95%)
Race						
White	929 (62.14%)	1,519 (62.72%)	2,759 (62.72%)	2,292 (59.84%)	741 (64.49%)	8,240 (61.98%)
Black or African American	201 (13.44%)	284 (11.73%)	493 (11.21%)	442 (11.54%)	135 (11.75%)	1,555 (11.70%)
Asian	41 (2.74%)	96 (3.96%)	191 (4.34%)	103 (2.69%)	25 (2.18%)	456 (3.43%)
Native Hawaiian or Other Pacific Islander	5 (0.33%)	12 (0.50%)	19 (0.43%)	27 (0.70%)	2 (0.17%)	65 (0.49%)
American Indian or Alaska Native	14 (0.94%)	19 (0.78%)	37 (0.84%)	24 (0.63%)	4 (0.35%)	98 (0.74%)
Other Race	151 (10.10%)	230 (9.50%)	433 (9.84%)	326 (8.51%)	78 (6.79%)	1,218 (9.16%)
Unknown	154 (10.30%)	262 (10.82%)	467 (10.62%)	616 (16.08%)	164 (14.27%)	1,663 (12.51%)
Ethnicity						
Hispanic or Latino	166 (11.10%)	308 (12.72%)	576 (13.09%)	545 (14.23%)	152 (13.23%)	1,747 (13.14%)
Not Hispanic or Latino	1,161 (77.66%)	1,854 (76.55%)	3,353 (76.22%)	2,967 (77.47%)	922 (80.24%)	10,257 (77.15%)
Unknown	168 (11.24%)	260 (10.73%)	470 (10.68%)	318 (8.30%)	75 (6.53%)	1,291 (9.71%)
Comorbidity						
Asthma	239 (15.99%)	393 (16.23%)	711 (16.16%)	630 (16.45%)	184 (16.01%)	2,157 (16.22%)
Chronic Lung Disease	146 (9.77%)	272 (11.23%)	435 (9.89%)	437 (11.41%)	130 (11.31%)	1,420 (10.68%)
Chronic Obstructive Pulmonary Disease	321 (21.47%)	522 (21.55%)	934 (21.23%)	924 (24.13%)	320 (27.85%)	3,021 (22.72%)

Hospitalization rate over time

The rate of parainfluenza-associated hospitalization is shown in Figure 16. Figure 17 shows seasonal trends.

Figure 16: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions since October 2020

Figure 17: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 1,751,758 parainfluenza lab results with known results of which 62,402 were positive. The parainfluenza test positivity rate is shown in Figure 18. Figure 19 shows yearly trends.

Figure 18: Weekly parainfluenza test positivity rate since October 2020

Figure 19: Weekly parainfluenza test positivity rate by season

Weekly parainfluenza test positivity rate by season

Respiratory syncytial virus (RSV)

Our RSV study population consists of 40,477 hospitalizations of 31,852 unique patients (Table 6).

Table 6: RSV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	2,038 (100.00%)	4,451 (100.00%)	8,082 (100.00%)	10,194 (100.00%)	7,087 (100.00%)	31,852 (100.00%)
Age Group						
< 6 months	503 (24.68%)	800 (17.97%)	1,392 (17.22%)	1,082 (10.61%)	418 (5.90%)	4,195 (13.17%)
6 - <12 months	134 (6.58%)	287 (6.45%)	504 (6.24%)	430 (4.22%)	275 (3.88%)	1,630 (5.12%)
1 - <2 years	183 (8.98%)	356 (8.00%)	561 (6.94%)	463 (4.54%)	325 (4.59%)	1,888 (5.93%)
2 - 4 years	163 (8.00%)	374 (8.40%)	725 (8.97%)	421 (4.13%)	339 (4.78%)	2,022 (6.35%)
5 - 17 years	47 (2.31%)	122 (2.74%)	253 (3.13%)	225 (2.21%)	132 (1.86%)	779 (2.45%)
18 - 49 years	188 (9.22%)	390 (8.76%)	623 (7.71%)	895 (8.78%)	746 (10.53%)	2,842 (8.92%)
50 - 64 years	264 (12.95%)	549 (12.33%)	946 (11.71%)	1,528 (14.99%)	1,135 (16.02%)	4,422 (13.88%)
65 - 74 years	243 (11.92%)	577 (12.96%)	1,108 (13.71%)	1,727 (16.94%)	1,282 (18.09%)	4,937 (15.50%)
75 - 84 years	194 (9.52%)	601 (13.50%)	1,166 (14.43%)	1,961 (19.24%)	1,440 (20.32%)	5,362 (16.83%)
85+ years	119 (5.84%)	395 (8.87%)	804 (9.95%)	1,462 (14.34%)	995 (14.04%)	3,775 (11.85%)
Sex						
Female	1,090 (53.48%)	2,283 (51.29%)	4,322 (53.48%)	5,591 (54.85%)	3,859 (54.45%)	17,145 (53.83%)
Male	939 (46.07%)	2,137 (48.01%)	3,687 (45.62%)	4,502 (44.16%)	3,152 (44.48%)	14,417 (45.26%)
Unknown	9 (0.44%)	31 (0.70%)	73 (0.90%)	101 (0.99%)	76 (1.07%)	290 (0.91%)
Race						
White	1,188 (58.29%)	2,833 (63.65%)	5,087 (62.94%)	6,375 (62.54%)	4,311 (60.83%)	19,794 (62.14%)
Black or African American	367 (18.01%)	518 (11.64%)	869 (10.75%)	1,081 (10.60%)	950 (13.40%)	3,785 (11.88%)
Asian	53 (2.60%)	200 (4.49%)	424 (5.25%)	349 (3.42%)	201 (2.84%)	1,227 (3.85%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Native Hawaiian or Other Pacific Islander	17 (0.83%)	76 (1.71%)	144 (1.78%)	105 (1.03%)	109 (1.54%)	451 (1.42%)
American Indian or Alaska Native	15 (0.74%)	38 (0.85%)	61 (0.75%)	71 (0.70%)	46 (0.65%)	231 (0.73%)
Other Race	182 (8.93%)	331 (7.44%)	659 (8.15%)	641 (6.29%)	450 (6.35%)	2,263 (7.10%)
Unknown	216 (10.60%)	455 (10.22%)	838 (10.37%)	1,572 (15.42%)	1,020 (14.39%)	4,101 (12.88%)
Ethnicity						
Hispanic or Latino	281 (13.79%)	604 (13.57%)	1,201 (14.86%)	1,277 (12.53%)	956 (13.49%)	4,319 (13.56%)
Not Hispanic or Latino	1,535 (75.32%)	3,439 (77.26%)	6,131 (75.86%)	7,976 (78.24%)	5,669 (79.99%)	24,750 (77.70%)
Unknown	222 (10.89%)	408 (9.17%)	750 (9.28%)	941 (9.23%)	462 (6.52%)	2,783 (8.74%)
Comorbidity						
Asthma	236 (11.58%)	587 (13.19%)	1,066 (13.19%)	1,495 (14.67%)	1,146 (16.17%)	4,530 (14.22%)
Chronic Lung Disease	136 (6.67%)	312 (7.01%)	586 (7.25%)	863 (8.47%)	664 (9.37%)	2,561 (8.04%)
Chronic Obstructive Pulmonary Disease	282 (13.84%)	743 (16.69%)	1,394 (17.25%)	2,163 (21.22%)	1,537 (21.69%)	6,119 (19.21%)

Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 20. Figure 21 shows seasonal trends.

Figure 20: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2020

Figure 21: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 5,990,614 RSV lab results with known results of which 282,623 were positive. The RSV test positivity rate is shown in Figure 22. Figure 23 shows yearly trends.

Figure 22: Weekly RSV test positivity rate since October 2020

Figure 23: Weekly RSV test positivity rate by season

Rhinovirus

Our rhinovirus study population consists of 68,622 hospitalizations of 55,063 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	7,102 (100.00%)	9,832 (100.00%)	15,849 (100.00%)	15,030 (100.00%)	7,250 (100.00%)	55,063 (100.00%)
Age Group						
< 6 months	379 (5.34%)	693 (7.05%)	862 (5.44%)	698 (4.64%)	224 (3.09%)	2,856 (5.19%)
6 - <12 months	250 (3.52%)	383 (3.90%)	450 (2.84%)	380 (2.53%)	131 (1.81%)	1,594 (2.89%)
1 - <2 years	505 (7.11%)	789 (8.02%)	853 (5.38%)	685 (4.56%)	241 (3.32%)	3,073 (5.58%)
2 - 4 years	621 (8.74%)	1,252 (12.73%)	1,412 (8.91%)	1,000 (6.65%)	349 (4.81%)	4,634 (8.42%)
5 - 17 years	770 (10.84%)	1,210 (12.31%)	1,783 (11.25%)	1,473 (9.80%)	516 (7.12%)	5,752 (10.45%)
18 - 49 years	1,484 (20.90%)	1,444 (14.69%)	2,581 (16.28%)	2,699 (17.96%)	1,492 (20.58%)	9,700 (17.62%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
50 - 64 years	1,099 (15.47%)	1,263 (12.85%)	2,352 (14.84%)	2,350 (15.64%)	1,297 (17.89%)	8,361 (15.18%)
65 - 74 years	880 (12.39%)	1,234 (12.55%)	2,261 (14.27%)	2,353 (15.66%)	1,232 (16.99%)	7,960 (14.46%)
75 - 84 years	695 (9.79%)	957 (9.73%)	2,005 (12.65%)	2,024 (13.47%)	1,098 (15.14%)	6,779 (12.31%)
85+ years	419 (5.90%)	607 (6.17%)	1,290 (8.14%)	1,368 (9.10%)	670 (9.24%)	4,354 (7.91%)
Sex						
Female	3,547 (49.94%)	4,725 (48.06%)	7,837 (49.45%)	7,526 (50.07%)	3,603 (49.70%)	27,238 (49.47%)
Male	3,492 (49.17%)	5,024 (51.10%)	7,872 (49.67%)	7,338 (48.82%)	3,585 (49.45%)	27,311 (49.60%)
Unknown	63 (0.89%)	83 (0.84%)	140 (0.88%)	166 (1.10%)	62 (0.86%)	514 (0.93%)
Race						
White	4,144 (58.35%)	5,727 (58.25%)	9,162 (57.81%)	8,541 (56.83%)	4,366 (60.22%)	31,940 (58.01%)
Black or African American	1,101 (15.50%)	1,429 (14.53%)	2,239 (14.13%)	2,114 (14.07%)	1,075 (14.83%)	7,958 (14.45%)
Asian	261 (3.68%)	436 (4.43%)	687 (4.33%)	410 (2.73%)	135 (1.86%)	1,929 (3.50%)
Native Hawaiian or Other Pacific Islander	46 (0.65%)	63 (0.64%)	66 (0.42%)	69 (0.46%)	30 (0.41%)	274 (0.50%)
American Indian or Alaska Native	43 (0.61%)	63 (0.64%)	118 (0.74%)	76 (0.51%)	43 (0.59%)	343 (0.62%)
Other Race	824 (11.60%)	1,154 (11.74%)	1,784 (11.26%)	1,630 (10.84%)	644 (8.88%)	6,036 (10.96%)
Unknown	683 (9.62%)	960 (9.76%)	1,793 (11.31%)	2,190 (14.57%)	957 (13.20%)	6,583 (11.96%)
Ethnicity						
Hispanic or Latino	877 (12.35%)	1,393 (14.17%)	2,470 (15.58%)	2,510 (16.70%)	1,181 (16.29%)	8,431 (15.31%)
Not Hispanic or Latino	5,474 (77.08%)	7,496 (76.24%)	11,779 (74.32%)	11,190 (74.45%)	5,638 (77.77%)	41,577 (75.51%)
Unknown	751 (10.57%)	943 (9.59%)	1,600 (10.10%)	1,330 (8.85%)	431 (5.94%)	5,055 (9.18%)
Comorbidity						
Asthma	1,329 (18.71%)	1,682 (17.11%)	2,697 (17.02%)	2,630 (17.50%)	1,342 (18.51%)	9,680 (17.58%)
Chronic Lung Disease	660 (9.29%)	743 (7.56%)	1,237 (7.80%)	1,158 (7.70%)	712 (9.82%)	4,510 (8.19%)
Chronic Obstructive Pulmonary Disease	1,199 (16.88%)	1,441 (14.66%)	2,440 (15.40%)	2,441 (16.24%)	1,431 (19.74%)	8,952 (16.26%)

Hospitalization rate over time

The rate of rhinovirus-associated hospitalization is shown in Figure 24. Figure 25 shows seasonal trends.

Figure 24: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2020

Figure 25: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 1,631,597 rhinovirus lab results with known results of which 255,376 were positive. The rhinovirus test positivity rate is shown in Figure 26. Figure 27 shows yearly trends.

Figure 26: Weekly rhinovirus test positivity rate since October 2020

Figure 27: Weekly rhinovirus test positivity rate by season

Infants and children (age 0-4)

Our infants and children study population consists of 42,709 hospitalizations of 32,501 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	3,742 (100.00%)	7,766 (100.00%)	9,789 (100.00%)	7,592 (100.00%)	3,612 (100.00%)	32,501 (100.00%)
Age Group						
< 6 months	1,291 (34.50%)	2,480 (31.93%)	3,107 (31.74%)	2,432 (32.03%)	908 (25.14%)	10,218 (31.44%)
6 - <12 months	503 (13.44%)	1,111 (14.31%)	1,479 (15.11%)	1,244 (16.39%)	583 (16.14%)	4,920 (15.14%)
1 - <2 years	900 (24.05%)	1,691 (21.77%)	2,039 (20.83%)	1,702 (22.42%)	915 (25.33%)	7,247 (22.30%)
2 - 4 years	1,048 (28.01%)	2,484 (31.99%)	3,164 (32.32%)	2,214 (29.16%)	1,206 (33.39%)	10,116 (31.13%)
Sex						
Female	1,572 (42.01%)	3,229 (41.58%)	4,234 (43.25%)	3,295 (43.40%)	1,557 (43.11%)	13,887 (42.73%)
Male	2,169 (57.96%)	4,523 (58.24%)	5,545 (56.65%)	4,285 (56.44%)	2,050 (56.76%)	18,572 (57.14%)
Unknown	1 (0.03%)	14 (0.18%)	10 (0.10%)	12 (0.16%)	5 (0.14%)	42 (0.13%)
Race						
White	1,730 (46.23%)	3,727 (47.99%)	4,523 (46.20%)	3,378 (44.49%)	1,638 (45.35%)	14,996 (46.14%)
Black or African American	738 (19.72%)	1,298 (16.71%)	1,508 (15.41%)	1,185 (15.61%)	619 (17.14%)	5,348 (16.45%)
Asian	188 (5.02%)	507 (6.53%)	785 (8.02%)	481 (6.34%)	208 (5.76%)	2,169 (6.67%)
Native Hawaiian or Other Pacific Islander	72 (1.92%)	170 (2.19%)	204 (2.08%)	194 (2.56%)	118 (3.27%)	758 (2.33%)
American Indian or Alaska Native	30 (0.80%)	73 (0.94%)	115 (1.17%)	58 (0.76%)	23 (0.64%)	299 (0.92%)
Other Race	686 (18.33%)	1,235 (15.90%)	1,581 (16.15%)	1,205 (15.87%)	569 (15.75%)	5,276 (16.23%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Unknown	298 (7.96%)	756 (9.73%)	1,073 (10.96%)	1,091 (14.37%)	437 (12.10%)	3,655 (11.25%)
Ethnicity						
Hispanic or Latino	762 (20.36%)	1,652 (21.27%)	2,452 (25.05%)	1,934 (25.47%)	944 (26.14%)	7,744 (23.83%)
Not Hispanic or Latino	2,684 (71.73%)	5,540 (71.34%)	6,600 (67.42%)	5,081 (66.93%)	2,411 (66.75%)	22,316 (68.66%)
Unknown	296 (7.91%)	574 (7.39%)	737 (7.53%)	577 (7.60%)	257 (7.12%)	2,441 (7.51%)
Virus						
COVID	616 (16.46%)	1,737 (22.37%)	1,076 (10.99%)	1,160 (15.28%)	804 (22.26%)	5,393 (16.59%)
HMPV	23 (0.61%)	430 (5.54%)	630 (6.44%)	358 (4.72%)	75 (2.08%)	1,516 (4.66%)
RSV	983 (26.27%)	1,817 (23.40%)	3,182 (32.51%)	2,396 (31.56%)	1,357 (37.57%)	9,735 (29.95%)
influenza	8 (0.21%)	135 (1.74%)	535 (5.47%)	432 (5.69%)	320 (8.86%)	1,430 (4.40%)
parainfluenza	357 (9.54%)	530 (6.82%)	789 (8.06%)	483 (6.36%)	111 (3.07%)	2,270 (6.98%)
rhinovirus	1,755 (46.90%)	3,117 (40.14%)	3,577 (36.54%)	2,763 (36.39%)	945 (26.16%)	12,157 (37.41%)
Comorbidity						
Asthma	282 (7.54%)	491 (6.32%)	653 (6.67%)	516 (6.80%)	328 (9.08%)	2,270 (6.98%)
Chronic Lung Disease	22 (0.59%)	42 (0.54%)	61 (0.62%)	59 (0.78%)	23 (0.64%)	207 (0.64%)
Chronic Obstructive Pulmonary Disease	4 (0.11%)	12 (0.15%)	13 (0.13%)	15 (0.20%)	1 (0.03%)	45 (0.14%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 28. Figure 29 shows the same data stacked to represent the combined impact of the viruses.

Figure 28: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five

Figure 29: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five

Test positivity rate over time

We included 5,318,513 lab results with known results of infants and children under age five. Of those tests, 606,164 lab results were positive. The test positivity rate for infants and children under age five is shown in Figure 30.

Figure 30: Weekly test positivity rate since October 2020 for infants and children under five

Older adults (age 65 and over)

Our older adults study population consists of 394,477 hospitalizations of 365,798 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	86,054 (100.00%)	95,649 (100.00%)	76,098 (100.00%)	72,500 (100.00%)	35,497 (100.00%)	365,798 (100.00%)
Age Group						
65 - 74 years	36,742 (42.70%)	36,776 (38.45%)	25,153 (33.05%)	24,040 (33.16%)	12,568 (35.41%)	135,279 (36.98%)
75 - 84 years	31,349 (36.43%)	35,806 (37.43%)	29,566 (38.85%)	28,597 (39.44%)	13,855 (39.03%)	139,173 (38.05%)
85+ years	17,963 (20.87%)	23,067 (24.12%)	21,379 (28.09%)	19,863 (27.40%)	9,074 (25.56%)	91,346 (24.97%)
Sex						

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Female	42,062 (48.88%)	48,078 (50.27%)	40,078 (52.67%)	37,955 (52.35%)	19,058 (53.69%)	187,231 (51.18%)
Male	43,688 (50.77%)	47,199 (49.35%)	35,645 (46.84%)	34,044 (46.96%)	16,093 (45.34%)	176,669 (48.30%)
Unknown	304 (0.35%)	372 (0.39%)	375 (0.49%)	501 (0.69%)	346 (0.97%)	1,898 (0.52%)
Race						
White	61,251 (71.18%)	71,419 (74.67%)	56,766 (74.60%)	50,461 (69.60%)	25,037 (70.53%)	264,934 (72.43%)
Black or African American	6,528 (7.59%)	7,093 (7.42%)	5,365 (7.05%)	5,579 (7.70%)	3,123 (8.80%)	27,688 (7.57%)
Asian	1,561 (1.81%)	1,756 (1.84%)	1,936 (2.54%)	1,740 (2.40%)	794 (2.24%)	7,787 (2.13%)
Native Hawaiian or Other Pacific Islander	147 (0.17%)	184 (0.19%)	161 (0.21%)	151 (0.21%)	72 (0.20%)	715 (0.20%)
American Indian or Alaska Native	242 (0.28%)	319 (0.33%)	311 (0.41%)	277 (0.38%)	145 (0.41%)	1,294 (0.35%)
Other Race	3,072 (3.57%)	2,817 (2.95%)	2,904 (3.82%)	2,818 (3.89%)	1,295 (3.65%)	12,906 (3.53%)
Unknown	13,253 (15.40%)	12,061 (12.61%)	8,655 (11.37%)	11,474 (15.83%)	5,031 (14.17%)	50,474 (13.80%)
Ethnicity						
Hispanic or Latino	4,576 (5.32%)	4,102 (4.29%)	4,229 (5.56%)	4,774 (6.58%)	2,519 (7.10%)	20,200 (5.52%)
Not Hispanic or Latino	66,738 (77.55%)	77,887 (81.43%)	62,078 (81.58%)	59,936 (82.67%)	30,471 (85.84%)	297,110 (81.22%)
Unknown	14,740 (17.13%)	13,660 (14.28%)	9,791 (12.87%)	7,790 (10.74%)	2,507 (7.06%)	48,488 (13.26%)
Virus						
COVID	82,722 (96.13%)	86,574 (90.51%)	53,771 (70.66%)	46,314 (63.88%)	11,195 (31.54%)	280,576 (76.70%)
HMPV	30 (0.03%)	1,085 (1.13%)	2,163 (2.84%)	1,923 (2.65%)	567 (1.60%)	5,768 (1.58%)
RSV	556 (0.65%)	1,573 (1.64%)	3,078 (4.04%)	5,150 (7.10%)	3,717 (10.47%)	14,074 (3.85%)
influenza	175 (0.20%)	2,573 (2.69%)	9,382 (12.33%)	11,269 (15.54%)	16,395 (46.19%)	39,794 (10.88%)
parainfluenza	577 (0.67%)	1,046 (1.09%)	2,148 (2.82%)	2,099 (2.90%)	623 (1.76%)	6,493 (1.78%)
rhinovirus	1,994 (2.32%)	2,798 (2.93%)	5,556 (7.30%)	5,745 (7.92%)	3,000 (8.45%)	19,093 (5.22%)
Comorbidity						
Asthma	6,545 (7.61%)	8,372 (8.75%)	7,966 (10.47%)	8,409 (11.60%)	4,637 (13.06%)	35,929 (9.82%)
Chronic Lung Disease	6,408 (7.45%)	7,487 (7.83%)	6,732 (8.85%)	6,859 (9.46%)	3,954 (11.14%)	31,440 (8.59%)
Chronic Obstructive Pulmonary Disease	14,704 (17.09%)	20,036 (20.95%)	17,496 (22.99%)	18,212 (25.12%)	9,872 (27.81%)	80,320 (21.96%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in `Figure 31. Figure 32 shows the same data stacked to represent the combined impact of the viruses.

Figure 31: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older

Figure 32: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older

Test positivity rate over time

We included 15,907,425 lab results with known results of adults aged 65 and over. Of those tests, 1,148,548 lab results were positive. The test positivity rate for adults aged 65 and over is shown in Figure 33.

Figure 33: Weekly test positivity rate since October 2020 for adults 65 years or older

Discussion and conclusion

In the week ending February 24, 2025, respiratory virus-associated hospitalizations accounted for 6.0% of all hospitalizations, marking a decline of 38.0% from late January,

when the rate was 9.6%. Influenza-associated hospitalizations reached a peak this month have started to decline; however, influenza-associated hospitalizations remain the leading cause of respiratory virus-associated hospitalizations among those studied in this report, with a current rate of 3.5%. COVID-associated hospitalizations also declined (-28.1%), along with parainfluenza (-30.6%), RSV (-21.4%), and rhinovirus (-2.1%). HMPV-associated hospitalizations saw a slight increase throughout February (+0.1 percentage points, 72.6% increase); however, test positivity for HMPV more than doubled (104.3%). While rhinovirus decreased overall throughout the month, the last week of February saw a slight increase and test positivity saw a 17.6% increase throughout the month. Parainfluenza test positivity also increased (34.6%) while test positivity for all other respiratory viruses decreased. Influenza test positivity remained high 16.3%.

In the population aged 0–4 years, respiratory virus-associated hospitalizations remained relatively stable between the weeks of January 27 and February 24, 2025, and are now at a rate of 4.9% of all hospitalizations in this age group. RSV-associated hospitalizations, which previously saw a high point before decreasing, saw a notable increase (+29.3%), now accounting for 1.9% of all hospitalizations. However, test positivity for RSV declined over the month (-24.2%). HMPV hospitalizations more than doubled (+111.2%), though they still represent a small fraction of the total hospitalizations (0.4% of all hospitalizations). Parainfluenza- and rhinovirus-associated hospitalizations also rose slightly. In contrast, influenza-associated hospitalizations dropped sharply (-47.2%), accounting for just 0.7% of hospitalizations in this group during the last week of February. COVID-associated hospitalizations remained relatively stable, with a slight increase of 8.6%. HMPV and parainfluenza test positivity saw the largest increases (+105.0% and +109.7%, respectively), while rhinovirus positivity also rose (+16.6%), reaching 29.9%—the highest test positivity among all viruses studied. Meanwhile, influenza test positivity saw a sharp decline (-32.0%). COVID test positivity remained stable, with a slight increase of 1.7%.

Among older adults (age 65 and over), respiratory virus-associated hospitalizations declined by 37.4% between the weeks of January 27 and February 24, 2025, now accounting for 7.5% of all hospitalizations in this age group. While most virus-associated hospitalizations decreased, HMPV hospitalizations rose (+71.4%), though they still represent a small fraction of overall hospitalizations (0.2% of all hospitalizations in this age group). Influenza-associated hospitalizations saw the largest decline (-46.3%), however it remains the virus associated with the most hospitalizations at 4.5% of all hospitalizations in this age group. COVID- (-29.9%) and RSV-associated (-20.3%) hospitalizations also decreased over the month of February; however, both still make up 1.8% and 0.9% of all hospitalizations in this age group, respectively.

Parainfluenza and rhinovirus hospitalizations remained relatively stable, with only minor changes (-11.8% and -2.7%, respectively). HMPV test positivity experienced the most substantial increase (+81.5%), followed by a moderate rise in rhinovirus (+29.1%) and a slight uptick in parainfluenza (+10.8%). Meanwhile, influenza test positivity dropped considerably (-34.7%), alongside RSV (-16.5%) and COVID (-12.6%). Despite the decline, influenza test positivity rates remained the highest at a rate of 11.9%. Rhinovirus positivity also rose to 4.2%, making it another virus to watch in this age group.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed March 19, 2025. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. The Journal of Pediatrics, 137(6), 865-870. https://doi.org/10.1067/mpd.2000.110531

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. https://www.cdc.gov/flu/about/burden/past-seasons.html

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. https://www.cdc.gov/surveillance/nrevss/index.html

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. https://www.cdc.gov/rsv/research/rsv-net/dashboard.html

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., … Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620-e638. https://doi.org/10.1542/peds.2014-1666

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahon, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz225, https://doi.org/10.1093/ofid/ofz225

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57(8), 1069–1077. https://doi.org/10.1093/cid/cit471

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infectious Diseases, 4(1), ofw270. https://doi.org/10.1093/ofid/ofw270

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., … Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. https://doi.org/10.1016/S0140-6736(17)30938-8

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine.

2023 Apr 6;41(15):2447-2455. https://doi.org/10.1016/j.vaccine.2023.02.038. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511-1518. https://doi.org/10.1093/cid/cix1060. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy